Abbott Laboratories stated in a regulatory filing that it intends to pay $184 million to settle class-action claims from pharmacies, wholesalers and generic-drug firms alleging that the company breached antitrust laws by working to block the launch of copies of its cholesterol drug TriCor. Abbott contends that it acted in accordance with the law and agreed to the settlement "to avoid the uncertainty of a trial outcome," a company spokeswoman said.

Related Summaries